https://staging.asieris.com/news/ 2025-09-04T21:44:33+00:00 https://staging.asieris.com/asieris-received-china-nmpas-approval-to-start-a-global-phase-iii-clinical-trial-for-apl-1702-to-treat-cervical-precancerous-lesions-hsil/ 2020-09-14T12:04:57+00:00 https://staging.asieris.com/asieris-pharmaceuticals-to-participate-at-cbiic/ 2020-09-14T12:08:17+00:00 https://staging.asieris.com/asieris-debuted-cevira-at-2019-coga/ 2020-09-14T12:25:58+00:00 https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2019-08-16-cevira-coga-conference-room.jpg https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2019-08-16-cevira-coga-conference-team.jpg https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2019-08-16-cevira-coga-conference-booths.png https://staging.asieris.com/asieris-and-photocure-enter-into-a-license-agreement-for-world-wide-development-and-commercialization-of-cevira/ 2020-09-14T12:27:41+00:00 https://staging.asieris.com/asieris-announces-completion-of-enrollment-for-its-us-apl-1202-phase-ib-clinical-trial/ 2020-09-14T12:28:55+00:00 https://staging.asieris.com/asieriss-executives-to-participate-in-the-upcoming-asia-pharma-rd-leaders-summit-2019/ 2020-09-14T12:29:45+00:00 https://staging.asieris.com/asieris-to-participate-in-the-upcoming-12th-european-life-sciences-ceo-forum/ 2020-09-14T15:55:28+00:00 https://staging.asieris.com/asieris-announced-appointment-of-dr-gail-brown-as-acting-chief-medical-officer/ 2020-09-14T15:56:44+00:00 https://staging.asieris.com/asieris-awarded-best-poster-at-aua-2018-annual-meeting/ 2020-09-14T15:57:43+00:00 https://staging.asieris.com/notice-of-relocation-of-our-shanghai-office/ 2020-09-14T16:17:11+00:00 https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2018-04-24-shanghai-office-entrance.jpg https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2018-04-24-shanghai-office-desk-area.jpg https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2018-04-24-shanghai-office-labratory-corridor.jpg https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2018-04-24-shanghai-office-multifunction-area.jpg https://staging.asieris.com/asieris-pharmaceuticals-invited-to-participate-at-bio-partnering-apac-2017/ 2020-09-14T16:22:12+00:00 https://staging.asieris.com/asieris-pharmaceuticals-invited-to-present-at-the-20th-annual-meeting-of-csco/ 2020-09-14T16:30:40+00:00 https://staging.asieris.com/asieris-pharmaceuticals-participated-at-2017-bio-international-convention/ 2020-09-14T16:33:32+00:00 https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2017-07-17-bio-international-convention-forum.png https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2017-07-17-bio-international-convention-booth-beginning.png https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2017-07-17-bio-international-convention-booth.png https://staging.asieris.com/asieris-pharmaceuticals-to-participate-at-2017-bio-international-convention/ 2020-09-14T16:34:55+00:00 https://staging.asieris.com/asieris-pharmaceuticals-presented-at-the-2017-chinabio-partnering-forum/ 2020-09-14T16:37:10+00:00 https://staging.asieris.com/asieris-announced-initiation-of-apl-1202-pivotal-clinical-trial/ 2020-09-14T16:52:18+00:00 https://staging.asieris.com/asieris-pharmaceuticals-is-invited-to-present-at-the-china-bio-partnership-forum-2016/ 2020-09-14T16:53:31+00:00 https://staging.asieris.com/scenes-at-the-european-association-of-urology-eau-2016-congress/ 2020-09-14T17:13:45+00:00 https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2016-03-01-european-association-urology-congress.png https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2016-03-01-european-association-urology-congress-slide.png https://staging.asieris.com/interim-results-of-china-phase-ii-clinical-trial-of-apl-1202-accepted-for-presentation/ 2020-09-14T17:58:28+00:00 https://staging.asieris.com/asieris-nominated-as-one-of-jiangsus-innovation-and-entrepreneurship-top-60-smes/ 2020-09-14T17:59:18+00:00 https://staging.asieris.com/asieris-completed-enrollment-for-its-china-phase-ii-trial-of-apl-1202/ 2020-09-14T18:00:21+00:00 https://staging.asieris.com/asieris-won-a-small-to-midium-size-technological-enterprise-sme-in-jiangsu/ 2020-09-14T18:01:43+00:00 https://staging.asieris.com/dr-kevin-pan-was-selected-as-a-member-of-113-talent-program/ 2020-09-14T18:02:41+00:00 https://staging.asieris.com/dr-yuh-visited-nanjing-idatastat-the-cro-for-apl-1202s-china-phase-ii-trial/ 2020-09-14T18:04:19+00:00 https://staging.asieris.com/asieris-held-an-investigators-meeting-for-apl-1202s-phase-ii-clinical-trial-in-china/ 2020-09-14T18:08:54+00:00 https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2013-12-01-investigator-meeting-apl-1202-phase-2-clinical-trial-china-1.png https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2013-12-01-investigator-meeting-apl-1202-phase-2-clinical-trial-china-2.png https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2013-12-01-investigator-meeting-apl-1202-phase-2-clinical-trial-china-3.png https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2013-12-01-investigator-meeting-apl-1202-phase-2-clinical-trial-china-4.png https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2013-12-01-investigator-meeting-apl-1202-phase-2-clinical-trial-china-5.png https://staging.asieris.com/asieris-achieved-objectives-in-the-grant-of-supporting-science-and-technology/ 2020-09-14T18:10:57+00:00 https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2013-11-01-supporting-science-technology-forum-slide.png https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2013-11-01-supporting-science-technology-forum.png https://staging.asieris.com/asieris-presented-at-the-fourth-china-taizhou-international-medical-expo/ 2020-09-14T18:12:10+00:00 https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2013-08-01-fourth-china-taizhou-international-medical-expo.png https://staging.asieris.com/september-2012-jiangsu-fda-inspected-apl-1202s-cro/ 2020-09-14T18:13:35+00:00 https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2012-09-20-jiangsu-fda-apl-1202.png https://staging.asieris.com/asieris-pharmaceuticals-establish-collabration-with-us-chinese-anti-cancer-association/ 2020-09-14T18:15:21+00:00 https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2010-06-01-establish-collaboration-us-china-anti-cancer-association-1.png https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2010-06-01-establish-collaboration-us-china-anti-cancer-association-2.png https://staging.asieris.com/asieris-pharmaceuticals-invited-to-be-a-panelist-at-the-aprdl-2018/ 2020-09-27T21:07:42+00:00 https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2018-04-08-aprdl-conference.jpg https://staging.asieris.com/asieris-ceo-to-host-ceo-roundtable-at-upcoming-wuxi-healthcare-forum-2019/ 2020-09-29T16:31:58+00:00 https://staging.asieris.com/asieris-announces-approval-of-its-phase-iii-trial-of-a-novel-single-oral-agent-as-first-line-treatment-for-non-muscle-invasive-bladder-cancer-nmibc/ 2020-11-04T18:15:40+00:00 https://staging.asieris.com/asieris-announces-first-patient-enrollment-in-the-global-phase-iii-clinical-trial-for-apl-1702/ 2020-11-17T20:53:44+00:00 https://staging.asieris.com/company-name-change-announcement/ 2020-12-15T20:11:13+00:00 https://staging.asieris.com/asieris-appointed-dr-xue-yong-as-chief-medical-officer-and-mr-jiang-xinming-as-vp-of-sales-and-marketing/ 2021-02-05T05:03:15+00:00 https://staging.asieris.com/asieris-to-present-at-6th-annual-drug-repositioning-repurposing-and-rescue-conference/ 2021-02-08T03:55:29+00:00 https://staging.asieris.com/asieris-announced-first-patient-in-apl-1202-pivotal-trial/ 2021-02-08T03:59:41+00:00 https://staging.asieris.com/asieris-apl-1501-approved-for-phase-i-clinical-trial-in-australia/ 2021-02-08T04:10:31+00:00 https://staging.asieris.com/asieris-and-lecheng-sinopharm-entered-into-a-strategic-cooperation-agreement/ 2021-03-26T02:04:24+00:00 https://staging.asieris.com/asieris-and-beigene-enter-into-clinical-collaboration-to-evaluate-combinations-of-apl-1202-and-tislelizumab/ 2021-05-07T02:04:50+00:00 https://staging.asieris.com/asieris-and-photocure-expand-strategic-partnership-to-bladder-cancer-diagnosis-and-surgery-in-mainland-china-and-taiwan/ 2021-05-12T05:14:38+00:00 https://staging.asieris.com/asieris-and-sinopharm-enter-into-strategic-partnership-to-accelerate-commercialization-of-asieris-products/ 2021-05-21T03:27:40+00:00 https://staging.asieris.com/asieris-wins-fierce-innovation-awards-life-sciences-edition-2019/ 2021-10-01T07:49:00+00:00 https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2019-12-19-fierce-innovation-conference.png https://staging.asieris.com/the-cde-approved-ind-application-to-investigate-combination-of-asieris-apl-1202-and-beigenes-tislelizumab-as-neoadjuvant-therapy-for-mibc-patients/ 2021-10-13T07:17:55+00:00 https://staging.asieris.com/asieris-named-one-of-top-30-chinese-innovative-enterprises-in-small-molecule-drugs/ 2021-10-15T02:05:35+00:00 https://staging.asieris.com/asieris-awarded-the-top-100-china-innovative-pharmaceutical-enterprises/ 2021-11-15T03:33:10+00:00 https://staging.asieris.com/wp-content/uploads/2020/12/asieris_pharmaceuticals_2020_award.png https://staging.asieris.com/asieris-announces-the-worlds-first-patient-dose-administered-in-combination-of-asierisapl-1202-and-beigenes-tislelizumab-as-neoadjuvant-therapy-for-mibc-patients/ 2022-01-04T02:48:35+00:00 https://staging.asieris.com/asieris-to-increase-presence-at-asco-gu-2022/ 2022-02-21T07:58:15+00:00 https://staging.asieris.com/2022-asco-asieris-presented-a-study-protocol-of-muscle-invasive-bladder-cancermibc/ 2022-06-05T04:42:10+00:00 https://staging.asieris.com/wp-content/uploads/2022/06/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_202206051045372.jpg https://staging.asieris.com/wp-content/uploads/2022/06/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20220605120916.jpg https://staging.asieris.com/wp-content/uploads/2022/06/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_202206051045371.jpg https://staging.asieris.com/asieris-to-publish-a-study-protocol-of-cevira-as-a-novel-treatment-in-patients-with-high-grade-squamous-intraepithelial-lesion-hsil-on-bmj-open/ 2022-06-09T05:37:22+00:00 https://staging.asieris.com/wp-content/uploads/2022/06/BMJ.png https://staging.asieris.com/asieris-multinational-phase-iii-clinical-trial-for-the-non-surgical-treatment-of-hsil-has-completed-enrollment/ 2022-08-09T07:30:22+00:00 https://staging.asieris.com/the-first-domestic-case-in-boao-ushering-in-a-new-option-for-diagnosing-bladder-cancer/ 2022-08-12T02:50:11+00:00 https://staging.asieris.com/wp-content/uploads/2022/08/Uro-G-Deflection-1024x390-1.jpg https://staging.asieris.com/wp-content/uploads/2022/08/2101-%E5%9B%BE.jpg https://staging.asieris.com/asieris-on-science-and-technology-innovation-board-2022-most-innovative-companies-list/ 2022-09-02T01:44:37+00:00 https://staging.asieris.com/wp-content/uploads/2022/09/%E4%BA%9A%E8%99%B9%E5%8C%BB%E8%8D%AF%E5%85%A5%E9%80%892022%E6%9C%80%E5%85%B7%E5%88%9B%E6%96%B0%E5%8A%9B%E7%A7%91%E5%88%9B%E6%9D%BF%E4%B8%8A%E5%B8%82%E5%85%AC%E5%8F%B8-225x300.jpg https://staging.asieris.com/hexvix-a-diagnostic-drug-of-asieris-is-now-covered-by-the-2022-lecheng-global-specialty-drug-insurance/ 2022-09-15T07:30:05+00:00 https://staging.asieris.com/asieris-pharmaceuticals-announces-2021-annual-report-steady-progress-in-core-product-pipeline-and-progressive-implementation-of-the-integrated-diagnosis-and-treatment-commercialization-strategy-2/ 2022-10-27T18:59:51+00:00 https://staging.asieris.com/asieris-initiated-tv-interview-for-apl-1202-china-phase-2-clinical-trial/ 2022-10-27T19:00:47+00:00 https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2014-06-01-apl-1202-china-phase-clinical-trial.png https://staging.asieris.com/tv-interview-at-kick-off-meeting-for-the-pivotal-trial-of-asieris-anti-bladder-cancer-drug/ 2022-10-27T19:00:50+00:00 https://staging.asieris.com/asieris-pharmaceuticals-lands-on-star-market/ 2022-10-27T19:23:40+00:00 https://staging.asieris.com/wp-content/uploads/2022/01/shutterstock_1117168151.jpg https://staging.asieris.com/asieris-announces-the-completion-of-their-series-d-round-of-financing/ 2022-10-27T19:24:54+00:00 https://staging.asieris.com/asieris-announced-the-completion-of-series-c-round-financing-to-accelerate-the-commercialization/ 2022-10-27T19:25:18+00:00 https://staging.asieris.com/asieris-announced-the-completion-of-series-c-round-financing-to-accelerate-the-global-development-of-its-innovative-drugs/ 2022-10-27T19:25:24+00:00 https://staging.asieris.com/asieris-announced-follow-on-investment-to-its-b-round-funding/ 2022-10-27T19:25:59+00:00 https://staging.asieris.com/asieris-announced-closing-of-series-b-funding-round-in-excess-of-100-million-rmb/ 2022-10-27T19:26:21+00:00 https://staging.asieris.com/wp-content/uploads/2020/09/asieris-pharmaceuticals-news-2017-12-27-closing-series-b-funding.jpg https://staging.asieris.com/asieris-to-present-a-study-protocol-of-apl-1202-in-combination-with-beigenes-tislelizumab-as-neoadjuvant-therapynacfor-muscle-invasive-bladder-cancer-mibc-patients-at-2022/ 2022-10-27T19:54:10+00:00 https://staging.asieris.com/bladder-cancer-diagnosis-drug-hexvix-completed-first-patient-procedure-in-boao-lecheng/ 2022-10-27T19:54:29+00:00 https://staging.asieris.com/wp-content/uploads/2021/12/prescription.jpg https://staging.asieris.com/wp-content/uploads/2021/12/procedure.jpg https://staging.asieris.com/wp-content/uploads/2021/12/Hexvix.jpg https://staging.asieris.com/asieris-announces-first-patient-treated-in-europe-in-apricity-the-multinational-phase-iii-clinical-trial-of-apl-1702-cevira/ 2022-10-27T19:54:38+00:00 https://staging.asieris.com/hexvix-has-obtained-cde-approval-to-carry-out-clinical-real-world-evidence-study/ 2022-10-27T19:58:20+00:00 https://staging.asieris.com/hexvix-a-diagnostic-drug-for-bladder-cancer-of-asieris-completed-the-first-patient-dose-in-phase-iii-trial/ 2022-11-04T09:00:00+00:00 https://staging.asieris.com/hexvix-has-obtained-ind-approval/ 2022-11-08T20:29:24+00:00 https://staging.asieris.com/the-u-s-fda-approved-ind-application-to-investigate-combination-of-asieris-apl-1202-and-beigenes-tislelizumab-as-neoadjuvant-therapy-for-mibc-patients/ 2022-11-08T20:31:30+00:00 https://staging.asieris.com/asieris-pharmaceuticals-2022-q3-quarterly-report/ 2022-11-11T20:23:14+00:00 https://staging.asieris.com/asieris-pharmaceuticals-2022-q1-quarterly-report/ 2022-11-11T20:28:44+00:00 https://staging.asieris.com/the-oral-apl-1202-in-combination-with-pd-1-inhibitor-tislelizumab-as-neoadjuvant-therapy-has-entered-phase-ii-clinical-study/ 2022-11-11T08:16:47+00:00 https://staging.asieris.com/first-ibcc-unveiled-in-hainan/ 2022-12-03T06:32:32+00:00 https://staging.asieris.com/wp-content/uploads/2022/12/%E5%90%88%E7%85%A7-1024x692.jpg https://staging.asieris.com/now-hiring-biomarker-scientist-onsite-mountain-view/ 2022-12-04T20:39:26+00:00 https://staging.asieris.com/now-hiring-business-development-director-remote/ 2022-12-04T20:40:22+00:00 https://staging.asieris.com/now-hiring-protein-scientist-onsite-mountain-view/ 2022-12-04T20:40:42+00:00 https://staging.asieris.com/now-hiring-research-associate-or-sr-ra-onsite-mountain-view/ 2022-12-04T20:40:52+00:00 https://staging.asieris.com/now-hiring-lab-manager-san-francisco/ 2022-12-04T20:40:56+00:00 https://staging.asieris.com/now-hiring-biology-director-san-francisco/ 2022-12-04T20:41:51+00:00 https://staging.asieris.com/now-hiring-scientist-senior-scientist-san-francisco/ 2022-12-04T20:41:59+00:00 https://staging.asieris.com/now-hiring-lab-office-manager-san-francisco/ 2022-12-04T20:42:06+00:00 https://staging.asieris.com/now-hiring-clinical-pharmacologist/ 2022-12-04T20:42:11+00:00 https://staging.asieris.com/now-hiring-bioinformatics-scientist-onsite-mountain-view/ 2022-12-04T20:42:22+00:00 https://staging.asieris.com/now-hiring-head-of-toxicology-director-to-senior-director-shanghai-or-san-francisco/ 2022-12-04T20:42:48+00:00 https://staging.asieris.com/now-hiring-research-associate-senior-research-associate/ 2022-12-04T20:42:55+00:00 https://staging.asieris.com/asieris-named-on-list-of-2022-top-20-most-influential-innovative-enterprises-in-small-molecule-drugs/ 2022-12-05T22:04:38+00:00 https://staging.asieris.com/asieris-appoints-dr-badrinath-konety-to-scientific-advisory-board/ 2022-12-06T08:53:09+00:00 https://staging.asieris.com/wp-content/uploads/2022/08/Dr.-Badrinath-Konety-scaled.jpg https://staging.asieris.com/wp-content/uploads/2022/08/Dr.-Badrinath-Konety-1024x768.jpg https://staging.asieris.com/asieris-pharmaceuticals-announces-2021-annual-report-steady-progress-in-core-product-pipeline-and-progressive-implementation-of-the-integrated-diagnosis-and-treatment-commercialization-strategy/ 2022-12-06T08:53:17+00:00 https://staging.asieris.com/asieris-appoints-dr-tie-lin-wang-as-senior-vice-president-head-of-discovery-chemistry-and-pre-clinical-development/ 2022-12-06T08:55:02+00:00 https://staging.asieris.com/asieris-appointed-dr-susan-wang-as-senior-vice-president-of-global-business-development/ 2022-12-06T08:55:40+00:00 https://staging.asieris.com/asieris-announced-appointment-of-dr-yijun-deng-as-vp-of-new-drug-discovery/ 2022-12-06T08:55:57+00:00 https://staging.asieris.com/asieris-included-in-the-sse-star-biology-and-medicine-index/ 2022-12-06T08:57:59+00:00 https://staging.asieris.com/asieris-enrolled-first-patient-for-its-phase-ii-clinical-study-of-oral-apl-1202-in-combination-with-tislelizumab-a-pd-1-inhibitor-as-neoadjuvant-therapy-for-muscle-invasive-bladd/ 2022-12-12T09:08:06+00:00 https://staging.asieris.com/asierisbladder-cancer-diagnostic-drug-hexvix-completed-dosing-of-first-patient-in-real-world-clinical-study/ 2023-01-31T08:53:21+00:00 https://staging.asieris.com/asieris-and-revir-collaborate-in-oncology-therapeutics-using-rna-targeting-technologies/ 2023-02-08T02:34:34+00:00 https://staging.asieris.com/asieris-appoints-dr-linda-wu-as-chief-development-officer/ 2023-02-09T00:19:05+00:00 https://staging.asieris.com/wp-content/uploads/2023/01/LWU-683x1024.jpg https://staging.asieris.com/asieris-drug-plays-pivotal-role-to-help-ucsf-save-a-life/ 2023-02-17T10:40:49+00:00 https://staging.asieris.com/nmpa-accepted-the-registration-applications-for-uro-g-and-uro-3500/ 2023-02-21T02:19:28+00:00 https://staging.asieris.com/asieris-subsidiary-makes-significant-progress-in-its-commercialization-strategy-by-obtaining-the-drug-distribution-license/ 2023-04-10T08:03:28+00:00 https://staging.asieris.com/asieris-releases-2022-annual-report-make-steady-progress-in-its-clinical-development-global-expansion-to-treat-genitourinary-tumors-and-implementing-its-commercialization-strategy-to-provide-integr/ 2023-04-17T17:12:49+00:00 https://staging.asieris.com/highlights-of-asieris-2022-semi-annual-report/ 2023-04-17T18:53:33+00:00 https://staging.asieris.com/wp-content/uploads/2022/08/P1.jpg https://staging.asieris.com/wp-content/uploads/2022/08/P2.jpg https://staging.asieris.com/wp-content/uploads/2022/08/P3.jpg https://staging.asieris.com/wp-content/uploads/2022/08/P4.jpg https://staging.asieris.com/wp-content/uploads/2022/08/P5.jpg https://staging.asieris.com/wp-content/uploads/2022/08/P6.jpg https://staging.asieris.com/wp-content/uploads/2022/08/P7.jpg https://staging.asieris.com/wp-content/uploads/2022/08/P8.jpg https://staging.asieris.com/asieris-pharmaceuticals-2022-annual-report-highlights/ 2023-04-21T17:36:59+00:00 https://staging.asieris.com/wp-content/uploads/elementor/thumbs/%E4%BA%9A%E8%99%B9%E5%B9%B4%E6%8A%A5%E9%95%BF%E5%9B%BE_%E8%8B%B1%E6%96%87%E7%89%881-q55oyf9tzl31oeoygrsxrilv62alz8uo7co9fdj6dc.jpg https://staging.asieris.com/wp-content/uploads/elementor/thumbs/%E4%BA%9A%E8%99%B9%E5%B9%B4%E6%8A%A5%E9%95%BF%E5%9B%BE_%E8%8B%B1%E6%96%87%E7%89%882-q55oyj16qx86yujhutfg1hnpjls2u19ljva7chdlog.jpg https://staging.asieris.com/wp-content/uploads/elementor/thumbs/%E4%BA%9A%E8%99%B9%E5%B9%B4%E6%8A%A5%E9%95%BF%E5%9B%BE_%E8%8B%B1%E6%96%87%E7%89%883-q55oymsji9dc9ae18v1ybgpjx59jotoiwdw59l80zk.jpg https://staging.asieris.com/wp-content/uploads/elementor/thumbs/%E4%BA%9A%E8%99%B9%E5%B9%B4%E6%8A%A5%E9%95%BF%E5%9B%BE_%E8%8B%B1%E6%96%87%E7%89%884-q55oypm22rh7849xse9u0xzxpavnbwzpwrulpf3ugw.jpg https://staging.asieris.com/wp-content/uploads/elementor/thumbs/%E4%BA%9A%E8%99%B9%E5%B9%B4%E6%8A%A5%E9%95%BF%E5%9B%BE_%E8%8B%B1%E6%96%87%E7%89%885-scaled-q55oyx4rlfrhszz0khiukw3mgdul1htklt2hjmsp34.jpg https://staging.asieris.com/wp-content/uploads/elementor/thumbs/%E4%BA%9A%E8%99%B9%E5%B9%B4%E6%8A%A5%E9%95%BF%E5%9B%BE_%E8%8B%B1%E6%96%87%E7%89%886-q55oz1tyjlxxf1s6t1jzfcwxfb7f3zc8agbwy0lq80.jpg https://staging.asieris.com/wp-content/uploads/elementor/thumbs/%E4%BA%9A%E8%99%B9%E5%B9%B4%E6%8A%A5%E9%95%BF%E5%9B%BE_%E8%8B%B1%E6%96%87%E7%89%887-q55oz6j5hs4d13ld1ll49tq8e8k96guvz3lcceercw.jpg https://staging.asieris.com/wp-content/uploads/elementor/thumbs/%E4%BA%9A%E8%99%B9%E5%B9%B4%E6%8A%A5%E9%95%BF%E5%9B%BE_%E8%8B%B1%E6%96%87%E7%89%888-q55ozc66msc2yrd64o0vosazyjsggnh9zvi9826ebk.jpg https://staging.asieris.com/asieris-deepens-strategic-partnership-with-uroviu-to-further-develop-integrated-diagnosis-and-treatment-platform-for-bladder-cancer/ 2023-05-18T17:17:16+00:00 https://staging.asieris.com/wp-content/uploads/2023/05/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20230518135404-1-1024x243.jpg https://staging.asieris.com/asieris-progress-in-mibc-receives-renewed-attention-with-its-inclusion-in-asco-2023/ 2023-05-31T08:01:04+00:00 https://staging.asieris.com/wp-content/uploads/2023/05/asco.png https://staging.asieris.com/hexvix-a-diagnostic-drug-for-bladder-cancer-of-asieris-has-completed-the-phase-iii-bridging-trial-enrollment/ 2023-07-07T02:27:24+00:00 https://staging.asieris.com/hong-kong-department-of-health-has-approved-the-registration-applications-for-the-uro-g-and-uro-v-disposable-cystoscopic-system/ 2023-08-15T08:04:31+00:00 https://staging.asieris.com/wp-content/uploads/2023/08/uroG.jpg https://staging.asieris.com/wp-content/uploads/2023/08/urov.png https://staging.asieris.com/asieris-releases-2023-semi-annual-report/ 2023-08-22T19:43:03+00:00 https://staging.asieris.com/asieris-obtained-ind-approval-from-us-fda-for-apl-1401-a-new-drug-for-the-treatment-of-moderately-to-severely-active-ulcerative-colitis/ 2023-08-30T02:41:06+00:00 https://staging.asieris.com/asieris-obtained-ind-approval-from-nmpa-for-apl-1401-a-drug-for-the-treatment-of-moderately-to-severely-active-ulcerative-colitis/ 2023-08-30T03:06:54+00:00 https://staging.asieris.com/asieris-announces-positive-phase-iii-bridging-trial-of-hexvix-a-diagnostic-drug-for-bladder-cancer/ 2023-09-08T11:00:42+00:00 https://staging.asieris.com/asieris-new-drug-apl-1401-completes-first-administration-in-patient-with-moderately-to-severely-active-uc/ 2023-09-14T08:52:08+00:00 https://staging.asieris.com/the-first-non-vaccine-investigational-product-for-cervical-hsil-has-achieved-its-primary-endpoint/ 2023-09-20T07:45:34+00:00 https://staging.asieris.com/asieris-to-unveil-first-ever-results-of-the-phase-iii-clinical-study-for-apl-1706-an-imaging-drug-for-diagnosis-or-surgery-of-bladder-cancer-at-the-2023-siu-annual-meeting/ 2023-10-07T06:00:58+00:00 https://staging.asieris.com/asieris-unveiled-results-of-its-phase-iii-clinical-study-for-apl-1706-an-imaging-drug-for-diagnosis-or-surgery-of-bladder-cancer-at-the-siu-2023-congress/ 2023-10-12T08:30:12+00:00 https://staging.asieris.com/asierisfirst-product-dipaite-achieves-commercialization-and-launches-in-china-first-prescription-issued-in-shanghai/ 2023-10-26T02:53:55+00:00 https://staging.asieris.com/asieris-announces-nmpa-has-accepted-the-new-drug-application-for-apl-1706-an-imaging-drug-for-diagnosing-and-management-of-bladder-cancer/ 2023-11-29T09:02:27+00:00 https://staging.asieris.com/two-asieris-studies-in-the-field-of-bladder-cancer-selected-for-oral-and-poster-presentations-at-the-2024-american-society-of-clinical-oncology-genitourinary-cancer-symposium-potentially-offering-new/ 2023-12-15T07:30:30+00:00 https://staging.asieris.com/wp-content/uploads/2023/12/1202.jpg https://staging.asieris.com/wp-content/uploads/2023/12/1706-scaled.jpg https://staging.asieris.com/asieris-successfully-convenes-first-domestic-breast-cancer-care-forum-and-national-product-launch-conference-for-ouyoubi-in-shanghai/ 2023-12-19T00:06:15+00:00 https://staging.asieris.com/wp-content/uploads/2023/12/%E7%8E%8B%E6%B5%B7%E6%B3%A2-scaled.jpg https://staging.asieris.com/wp-content/uploads/2023/12/%E8%A2%81%E8%8A%83-scaled.jpg https://staging.asieris.com/wp-content/uploads/2023/12/%E7%A7%A6%E5%8D%9A-scaled.jpg https://staging.asieris.com/wp-content/uploads/2023/12/%E6%B1%9F-scaled.jpg https://staging.asieris.com/apl-2301-a-compound-developed-by-asieris-for-the-treatment-of-acinetobacter-baumannii-infection-was-approved-for-phase-i-clinical-trials-in-australia/ 2023-12-26T05:49:59+00:00 https://staging.asieris.com/enhancing-leadership-in-gynecology-asieris-pharmaceuticals-appoints-sophia-cao-to-lead-the-newly-established-womens-health-business-unit-accelerating-strategic-expansion/ 2024-01-08T08:08:17+00:00 https://staging.asieris.com/wp-content/uploads/2024/01/Sophia-%E6%9B%B9-1.jpg https://staging.asieris.com/asieris-announces-positive-interim-analysis-results-in-phase-ii-clinical-trial-of-oral-apl-1202-in-combination-with-tislelizumab-a-pd-1-inhibitor-as-neoadjuvant-therapy-for-muscl/ 2024-01-18T07:12:02+00:00 https://staging.asieris.com/asieris-releases-phase-iii-clinical-study-and-real-world-research-data-for-apl-1706-a-bladder-cancer-diagnosis-and-management-drug-at-the-2024-asco-gu/ 2024-01-30T01:37:33+00:00 https://staging.asieris.com/asieris-presents-for-the-first-time-interim-analysis-data-of-oral-apl-1202-in-combination-with-pd-1-inhibitor-tislelizumab-for-neoadjuvant-treatment-of-muscle-invasive-bladder-cancer-at-2024-asco-gu/ 2024-02-21T03:38:20+00:00 https://staging.asieris.com/asieris-will-present-for-the-first-time-interim-analysis-data-of-oral-apl-1202-in-combination-with-pd-1-inhibitor-tislelizumab-for-neoadjuvant-treatment-of-muscle-invasive-bladder-cancer-at-2024-asco/ 2024-02-21T03:41:18+00:00 https://staging.asieris.com/wp-content/uploads/2024/01/%E5%A4%96%E5%9B%BD%E4%BA%BA.jpg https://staging.asieris.com/asierisbreast-cancer-product-ouyoubi-makes-inaugural-landings-in-twenty-cities-steadily-advancing-domestic-commercialization-process/ 2024-02-21T03:44:46+00:00 https://staging.asieris.com/highlights-of-asieris-2023-semi-annual-report/ 2024-02-22T04:38:12+00:00 https://staging.asieris.com/wp-content/uploads/elementor/thumbs/%E4%BA%9A%E8%99%B92023%E5%8D%8A%E5%B9%B4%E6%8A%A5%E8%8B%B1%E6%96%87%E7%89%88%E8%A3%81%E5%88%87_1-qbb1br7kbimdr6lqrnssyk4j0payizgcb490xjdkhs.jpg https://staging.asieris.com/wp-content/uploads/elementor/thumbs/%E4%BA%9A%E8%99%B92023%E5%8D%8A%E5%B9%B4%E6%8A%A5%E8%8B%B1%E6%96%87%E7%89%88%E8%A3%81%E5%88%87_2-qbb1bt38p6oyeej0gom23jng7h1oydnszdjzw3as5c.jpg https://staging.asieris.com/wp-content/uploads/elementor/thumbs/%E4%BA%9A%E8%99%B92023%E5%8D%8A%E5%B9%B4%E6%8A%A5%E8%8B%B1%E6%96%87%E7%89%88%E8%A3%81%E5%88%87_3-qbb1bxsfncve0gc6p8n6y0gr6eej0v6go0tfah3ta8.jpg https://staging.asieris.com/wp-content/uploads/elementor/thumbs/%E4%BA%9A%E8%99%B92023%E5%8D%8A%E5%B9%B4%E6%8A%A5%E8%8B%B1%E6%96%87%E7%89%88%E8%A3%81%E5%88%87_4-qbb1c2hmlj1tmi5cxsobsha25brd3cp4co2uouwuf4.jpg https://staging.asieris.com/wp-content/uploads/elementor/thumbs/%E4%BA%9A%E8%99%B92023%E5%8D%8A%E5%B9%B4%E6%8A%A5%E8%8B%B1%E6%96%87%E7%89%88%E8%A3%81%E5%88%87_5-scaled-qbb1c68zcv6ywxzwbuau2gbwiv8ty541p6oslyr9q8.jpg https://staging.asieris.com/wp-content/uploads/elementor/thumbs/%E4%BA%9A%E8%99%B92023%E5%8D%8A%E5%B9%B4%E6%8A%A5%E8%8B%B1%E6%96%87%E7%89%88%E8%A3%81%E5%88%87_6-qbb1cay6b1deizt2kebywx57hslo0mmpdty80ckav4.jpg https://staging.asieris.com/wp-content/uploads/elementor/thumbs/%E4%BA%9A%E8%99%B92023%E5%8D%8A%E5%B9%B4%E6%8A%A5%E8%8B%B1%E6%96%87%E7%89%88%E8%A3%81%E5%88%87_7-qbb1cfnd97ju51m8syd3rdyigpyi345d2h7neqdc00.jpg https://staging.asieris.com/wp-content/uploads/elementor/thumbs/%E4%BA%9A%E8%99%B92023%E5%8D%8A%E5%B9%B4%E6%8A%A5%E8%8B%B1%E6%96%87%E7%89%88%E8%A3%81%E5%88%87_8-qbb1cm88l1suebcoqj7hquaqmf22kzvhfds1ro3ksg.jpg https://staging.asieris.com/asieris-to-unveil-first-ever-results-of-the-international-multicenter-phase-iii-clinical-study-for-1702-a-non-surgical-treatment-for-cervical-hsil-at-the-2024-eurogin/ 2024-02-22T07:31:49+00:00 https://staging.asieris.com/asieris-to-unveil-results-of-the-international-multicenter-phase-iii-clinical-study-for-1702-a-non-surgical-treatment-for-cervical-hsil-at-the-2024-sgo-annual-meeting/ 2024-02-23T07:31:39+00:00 https://staging.asieris.com/asieris-to-unveil-first-ever-results-of-the-international-multicenter-phase-iii-clinical-study-for-apl-1702-a-non-surgical-treatment-for-cervical-hsil-at-the-2024-eurogin-congress/ 2024-03-04T07:30:47+00:00 https://staging.asieris.com/wp-content/uploads/2024/03/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20240304135905.jpg https://staging.asieris.com/asieris-to-unveil-results-of-the-international-multicenter-phase-iii-clinical-study-for-apl-1702-a-non-surgical-treatment-for-cervical-hsil-at-the-2024-sgo-annual-meeting/ 2024-03-05T07:32:56+00:00 https://staging.asieris.com/wp-content/uploads/2024/02/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20240301141309.jpg https://staging.asieris.com/asieris-appoints-dr-alice-chen-as-vice-president-discovery-biology-and-head-of-translational-research/ 2024-03-05T12:33:15+00:00 https://staging.asieris.com/asieris-two-research-achievements-to-be-presented-at-the-2024-american-association-for-cancer-research-annual-meeting-exploring-more-treatment-possibilities/ 2024-03-11T07:44:22+00:00 https://staging.asieris.com/wp-content/uploads/2024/03/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20240311151200.jpg https://staging.asieris.com/breakthrough-in-treatment-of-cervical-high-grade-squamous-intraepithelial-lesion-release-of-positive-results-from-multicenter-phase-iii-global-clinical-study/ 2024-03-18T08:59:11+00:00 https://staging.asieris.com/asieris-pharmaceuticals-to-present-the-drug-and-equipment-performance-results-from-the-phase-iii-clinical-study-of-the-bladder-cancer-diagnostic-and-management-drug-apl-1706-in-combination-with-hd-4k/ 2024-04-01T07:30:23+00:00 https://staging.asieris.com/wp-content/uploads/2024/03/EAU22_emailheader_july-1.jpg https://staging.asieris.com/wp-content/uploads/2024/03/%E5%9B%BE%E7%89%871-scaled.jpg https://staging.asieris.com/asieris-pharmaceuticals-releases-the-drug-and-equipment-performance-results-from-the-phase-iii-clinical-study-of-the-bladder-cancer-diagnostic-and-management-drug-apl-1706-in-combination-with-hd-4k-bl/ 2024-04-08T10:30:26+00:00 https://staging.asieris.com/wp-content/uploads/2024/04/image-1.png https://staging.asieris.com/asieris-pharmaceuticals-unveils-2023-annual-report-core-product-apl-1702-succeeds-in-global-phase-iii-clinical-trials-apl-1706-obtains-nda-acceptance-domestically-specialty-commercial-team-generate/ 2024-04-17T14:22:18+00:00 https://staging.asieris.com/asieris-announces-nmpa-acceptance-of-nda-for-apl-1702-a-non-surgical-therapy-for-treating-cervical-hsil/ 2024-05-13T05:05:40+00:00 https://staging.asieris.com/asieris-publishes-latest-research-findings-on-apl-1401-for-the-treatment-of-active-ulcerative-colitis-in-cellular-immunology/ 2024-06-13T02:11:44+00:00 https://staging.asieris.com/wp-content/uploads/2024/06/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20240612154118.jpg https://staging.asieris.com/asieris-apl-1202-investigational-new-drug-ind-approved-by-nmpa-for-treating-free-living-amoebae-infections/ 2024-06-24T10:21:56+00:00 https://staging.asieris.com/asieris-pharmaceuticals-releases-2024-semi-annual-report-highlighting-steady-progress-in-launching-blockbuster-product-for-precancerous-cervical-lesions-and-continued-strengthening-of-commercial-reve/ 2024-08-28T12:39:04+00:00 https://staging.asieris.com/asieris-unveils-results-for-the-first-time-at-2024-pdtpd-conference-the-efficacy-data-of-non-surgical-treatment-of-cervical-hsil-with-apl-1702-in-reducing-the-histological-grade-of-cervical-preca/ 2024-09-17T10:01:21+00:00 https://staging.asieris.com/encouraging-efficacy-signals-achieved-in-phase-ii-clinical-trial-of-asieris-apl-1202-in-combination-with-pd-1-inhibitor-tislelizumab-for-neoadjuvant-therapy-in-muscle-invasive-bladder-cancer/ 2024-09-25T07:42:24+00:00 https://staging.asieris.com/asieris-unveils-results-for-the-first-time-at-2024-csco-conference-the-subgroup-analysis-of-pathological-regression-rate-and-hpv-clearance-rate-at-6-months-in-different-age-groups-of-the-non-surgical/ 2024-09-29T09:25:47+00:00 https://staging.asieris.com/asieris-pharmaceuticals-appoints-richard-zhao-as-senior-vice-president-of-business-development/ 2024-10-22T11:01:31+00:00 https://staging.asieris.com/wp-content/uploads/2024/10/%E8%B5%B5%E9%98%B3%E5%85%88%E7%94%9F-scaled.jpg https://staging.asieris.com/asieris-pharmaceuticals-and-ecusts-school-of-chemistry-and-molecular-engineering-forge-strategic-partnership-on-photodynamic-platforms/ 2024-10-22T12:37:36+00:00 https://staging.asieris.com/wp-content/uploads/2024/10/%E5%8D%8E%E7%90%86%E7%AD%BE%E7%BA%A64.jpg https://staging.asieris.com/wp-content/uploads/2024/10/%E5%8D%8E%E7%90%86%E7%AD%BE%E7%BA%A63.jpg https://staging.asieris.com/asieris-received-fda-ind-approval-for-a-novel-usp1-inhibitor-for-the-treatment-of-advanced-solid-tumors/ 2024-10-24T10:17:36+00:00 https://staging.asieris.com/asieris-showcases-worlds-1st-product-for-non-invasive-treatment-of-precancerous-cervical-lesions-at-its-ciie-debut/ 2024-11-05T14:27:20+00:00 https://staging.asieris.com/cancer-foundation-of-china-and-asieris-pharmaceuticals-forge-strategic-partnership-for-cervical-cancer-prevention-and-control/ 2024-11-06T14:35:00+00:00 https://staging.asieris.com/wp-content/uploads/2024/11/%E7%99%8C%E5%9F%BA%E4%BC%9A%E7%AD%BE%E7%BA%A6%E7%85%A711-scaled.jpg https://staging.asieris.com/asieris-pharmaceuticals-and-china-womens-development-foundation-sign-strategic-cooperation-agreement-for-fertility-friendly-cervical-health-initiative/ 2024-11-07T10:20:37+00:00 https://staging.asieris.com/wp-content/uploads/2024/11/%E5%A6%87%E5%9F%BA%E4%BC%9A%E7%AD%BE%E7%BA%A6%E7%85%A7%E7%89%87-scaled.jpg https://staging.asieris.com/asieris-hong-kong-and-sph-keyuan-trade-sign-strategic-cooperation-agreement-at-ciie/ 2024-11-07T10:42:28+00:00 https://staging.asieris.com/wp-content/uploads/2024/11/%E7%A7%91%E5%9B%AD%E7%AD%BE%E7%BA%A6%E7%85%A7%E7%89%87-scaled.jpg https://staging.asieris.com/asieris-unveils-results-for-the-first-time-at-2024-ipvc-the-analysis-of-the-of-hpv-clearance-rate-for-different-hpv-types-and-different-follow-up-times-of-the-non-surgical-treatment-for-cervical-hsil/ 2024-11-12T10:10:00+00:00 https://staging.asieris.com/wp-content/uploads/2024/11/%E5%9B%BE-1.png https://staging.asieris.com/asieris-pharmaceuticals-appoints-joanna-zhang-as-chief-medical-officer/ 2024-11-18T01:30:45+00:00 https://staging.asieris.com/wp-content/uploads/2024/11/%E5%BC%A0%E4%BA%91%E4%BF%AE%E5%90%8E.jpg https://staging.asieris.com/asieris-and-cdc-sign-investigational-product-supply-agreement-for-apl-1202-in-free-living-amoeba-infections-treatment-under-expanded-access-investigational-new-drug-program/ 2025-01-06T08:29:45+00:00 https://staging.asieris.com/asieris-pharmaceuticals-appoints-helen-xu-as-chief-commercial-officer/ 2025-01-13T01:09:55+00:00 https://staging.asieris.com/wp-content/uploads/2025/01/%E5%BE%90%E7%91%9B%E5%A5%B3%E5%A3%AB.jpg https://staging.asieris.com/asieris-received-nmpa-ind-approval-for-a-novel-usp1-inhibitor-for-the-treatment-of-advanced-solid-tumors/ 2025-01-16T08:52:31+00:00 https://staging.asieris.com/asieris-awarded-annual-star-of-innovation-at-the-5th-annual-lunjian-awards-2024/ 2025-01-22T07:59:38+00:00 https://staging.asieris.com/asieris-selected-as-the-top-10-exhibitors-with-communication-influence-in-the-innovation-incubation-special-section-of-the-7th-ciie/ 2025-01-24T09:11:36+00:00 https://staging.asieris.com/asieris-presents-phase-ii-clinical-study-results-of-apl-1202-in-combined-with-pd-1-inhibitor-tislelizumab-as-neoadjuvant-therapy-for-muscle-invasive-bladder-cancer-at-2025-asco-gu/ 2025-02-14T09:06:13+00:00 https://staging.asieris.com/asieris-apl-2302-completes-first-patient-enrollment-in-clinical-trial-for-advanced-solid-tumors/ 2025-03-13T09:32:35+00:00 https://staging.asieris.com/asieris-research-achievements-selected-for-presentation-at-the-2025-american-association-for-cancer-research-annual-meeting/ 2025-03-26T10:16:03+00:00 https://staging.asieris.com/wp-content/uploads/2025/03/AACR2025.png https://staging.asieris.com/asieris-subsidiary-baylink-biosciences-to-present-two-research-achievements-at-the-2025-american-association-for-cancer-research-annual-meeting/ 2025-03-27T09:39:13+00:00 https://staging.asieris.com/wp-content/uploads/2025/03/AACR2025-1.png https://staging.asieris.com/asieris-pharmaceuticals-releases-2024-annual-report-with-revenue-exceeding-rmb-200m-in-1st-year-of-commercialization-and-innovative-portfolio-accelerating-toward-launch/ 2025-04-18T13:23:21+00:00 https://staging.asieris.com/asieris-and-subsidiary-baylink-present-study-results-on-ai-small-molecules-and-adc-platform-at-the-2025-aacr-annual-meeting/ 2025-04-27T06:17:02+00:00 https://staging.asieris.com/asieris-to-present-worlds-innovative-photodynamic-products-at-19th-ipa-congress/ 2025-06-06T08:09:27+00:00 https://staging.asieris.com/wp-content/uploads/2025/06/cgi-bin_mmwebwx-bin_webwxgetmsgimg__MsgID9087629775746947477skey@crypt_1fb80dda_a73c414be365e361e5398327993b3637mmweb_appidwx_webfilehelper.jpg https://staging.asieris.com/wp-content/uploads/2025/06/cgi-bin_mmwebwx-bin_webwxgetmsgimg__MsgID3931785050025323199skey@crypt_1fb80dda_3241f1473f47622493f59ad7849e7cd0mmweb_appidwx_webfilehelper.jpg https://staging.asieris.com/19th-international-photodynamic-association-congressconcludes-successfully/ 2025-06-22T02:46:45+00:00 https://staging.asieris.com/wp-content/uploads/2025/06/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20250616092110-scaled.jpg https://staging.asieris.com/wp-content/uploads/2025/06/2025-06-15-105527.jpg https://staging.asieris.com/wp-content/uploads/2025/06/2025-06-15-105548.jpg https://staging.asieris.com/wp-content/uploads/2025/06/2025-06-15-113258.jpg https://staging.asieris.com/asieris-new-drug-apl-1401-demonstrates-positive-preliminary-results-in-phase-ib-clinical-trial-for-moderately-to-severely-active-uc/ 2025-08-01T09:43:53+00:00 https://staging.asieris.com/asieris-apl-1702-nda-advances-to-second-round-of-technical-review/ 2025-09-04T18:55:35+00:00 https://staging.asieris.com/asieris-pharmaceuticals-releases-2025-semi-annual-report-with-sustained-commercial-momentum-and-breakthrough-innovation-poised-for-launch/ 2025-09-04T21:44:33+00:00